Leaving the study early · patients with schizophrenia
COMPARISON 5. ARIPIPRAZOLE may leads to higher leaving the study early compared with OLANZAPINE (low certainty).
1 finding from 1 review
Quality of life: as · patients with schizophrenia
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes adverse effects: weight gain compared with OLANZAPINE (very low certainty).
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes adverse effects: extrapyramidal effects compared with CLOZAPINE (very low certainty).
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
COMPARISON 2. ARIPIPRAZOLE showed no clear difference in global state: No clinically significant response (as defined by… compared with QUETIAPINE (low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
It is very uncertain whether pericyazine changes global state ‐ not improved compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Behaviour ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether pericyazine changes adverse events ‐ for specific reasons ‐ Extrapyramidal side effect compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).
1 finding from 1 review